Fundraising Fox
ユナイテッド・イミュニティ株式会社
Founded 2017 · 17 employees on LinkedIn · 3 known investors
Find your way into ユナイテッド・イミュニティ株式会社
Sign up to see every warm intro you have to ユナイテッド・イミュニティ株式会社
- Paths you didn't know you had: your email and LinkedIn already hold routes to the ユナイテッド・イミュニティ株式会社 team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
United Immunity develops a myeloid-targeting platform using pullulan-based nanoparticles to selectively deliver therapeutic agents and vaccine antigens to macrophages and dendritic cells. The platform targets these immune cells through DC-SIGN receptor binding for cancer immunotherapy, vaccines, and treatment of fibrosis, viral infections, and inflammatory diseases.
Investors · 3
How we know: Nippon Venture Capital's portfolio page · Not right? Tell us
How we know: UTEC's portfolio page · Not right? Tell us
.png){kind=logo}
How we know: the VCSheet dataset · Not right? Tell us
Frequently asked questions
- What does ユナイテッド・イミュニティ株式会社 do?
- United Immunity develops a myeloid-targeting platform using pullulan-based nanoparticles to selectively deliver therapeutic agents and vaccine antigens to macrophages and dendritic cells. The platform targets these immune cells through DC-SIGN receptor binding for cancer immunotherapy, vaccines, and treatment of fibrosis, viral infections, and inflammatory diseases.
- Who are ユナイテッド・イミュニティ株式会社's investors?
- ユナイテッド・イミュニティ株式会社's investors include Nippon Venture Capital, UTEC, Aozora Corporate Investment.